ArticleChinese medicine2026
Chuangling Ye mitigates diabetic foot ulcer through suppressing keratinocyte ferroptosis via inhibiting ACSS2/ACSL4 axis.
Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundDiabetic foot ulcers (DFU) is a serious complication of diabetes, and keratinocyte ferroptosis has been shown to accelerate its pathological progression. Chuanglin Ye (CLY), widely used in clinical practice for the treatment of DFU, has been reported to exert anti-inflammation effects and promote skin regeneration. However, its pharmacological mechanisms on DFU remain unclear.
methodsThe DFU rats were treated with CLY (0.225 and 0.45 g/mL) for 21 days to evaluate its therapeutic efficacy. The chemical composition of CLY was analyzed using UPLC-MS/MS. Network pharmacology, western blot, and immunohistochemical staining were performed to assess the anti-ferroptosis effects of CLY. To validate the protective role of CLY against ferroptosis, RSL3, a ferroptosis inducer, was applied in this study. Subsequently, HaCaT cells were exposed to advanced glycation end products (AGEs) to establish an in vitro model of keratinocyte ferroptosis, further confirming the inhibitory effects of CLY on ferroptosis. RNA sequencing was conducted to elucidate the molecular mechanisms underlying CLY-mediated protection against keratinocyte ferroptosis. The functional involvement of the ACSS2/ACSL4 axis was verified through plasmid-mediated gene overexpression in vitro. Molecular docking analysis was employed to identify potential bioactive compounds in CLY that target ACSS2.
resultsCLY administration significantly accelerated wound healing in DFU rats. Network pharmacology analysis indicated the regulation of ferroptosis underlies the therapeutic effect of CLY against DFU, which was further supported by its ability to ameliorate lipid peroxidation and iron overload. In contrast, the ferroptosis inducer RSL3 attenuated the protective effects of CLY in DFU rats. In vitro, CLY markedly suppressed AGEs-induced lipid peroxidation and excessive ROS level. Mechanistically, RNA-seq analysis and subsequent validation experiments revealed the anti-ferroptosis effect of CLY depends on the inhibition of ACSL4 acetylation in keratinocytes. Furthermore, ACSS2 was identified as a key protein promoting ACSL4 acetylation, which was inhibiting by CLY. Finally, six major compounds in CLY were identified as active constituents targeting ACSS2.
conclusionOur findings demonstrate CLY promotes DFU wound healing by inhibiting keratinocyte ferroptosis through suppressing ACSS2-mediated ACSL4 acetylation, highlighting its potential as a rational therapeutic approach for the management of DFU.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.